<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>7834328</identifier>
<setSpec>0002-5151</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Ortíz Aldana, I</dc:author>
<dc:author>Arreguín Osuna, L</dc:author>
<dc:author>Isart Fagundo, E</dc:author>
<dc:author>Cariño Javier, R</dc:author>
<dc:author>Meza Morales, A</dc:author>
<dc:description xml:lang="en">Methotrexate represents a new therapeutic modality in patients with corticoresistant asthma. Its mechanism of action is the competitive inhibition of the folate reducing enzyme, converting folic acid in tetrahydrofolate during the S phase of the cell cycle. It is 50% fixed to albumin and excreted by glomerular filtration and proximal tubule secretion.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>1994 Nov-Dec </dc:date>
<dc:title xml:lang="es">Uso de methotrexate en el asma corticorresistente.</dc:title>
<dc:title xml:lang="en">[The use of methotrexate in cortico-resistant asthma].</dc:title>
<dc:publisher>Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)</dc:publisher>
</metadata>
</record>
</pubmed-document>
